Trials / Completed
CompletedNCT04398888
Efficacy of a Modified Banxia Xiexin Decoction for the "Wei-Pi" Syndrome (Postprandial Distress Syndrome)
Efficacy of a Modified Banxia Xiexin Decoction (BXD) for the "Wei-Pi" Syndrome (Postprandial Distress Syndrome): a Randomized, Waitlist Controlled Trial
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 88 (actual)
- Sponsor
- The University of Hong Kong · Academic / Other
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
The study aims to evaluate the efficacy of a modified Banxia Xiexin Decoction (BXD) for Wei-Pi through a randomized, waitlist controlled trial.
Detailed description
After being informed about the study plan, potential risk and benefits, all subjects will give written informed consent prior to participation and undergo eligibility screening. Eligible participants will be randomized, in a 1:1 ratio, into BXD group and waitlist group.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Banxie Xiexin Decoction (BXD) | A modified Banxie Xiexin Decoction based on Chinese medicine syndrome differentiation. |
Timeline
- Start date
- 2020-08-01
- Primary completion
- 2021-09-30
- Completion
- 2021-09-30
- First posted
- 2020-05-21
- Last updated
- 2022-07-29
Locations
1 site across 1 country: Hong Kong
Source: ClinicalTrials.gov record NCT04398888. Inclusion in this directory is not an endorsement.